Accolade Key Executives
This section highlights Accolade's key executives, including their titles and compensation details.
Find Contacts at Accolade
(Showing 0 of )
Accolade Earnings
This section highlights Accolade's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2025 | 2024-10-08 | $-0.45 | $-0.30 |
| Read Transcript | Q1 | 2025 | 2024-06-27 | $-0.48 | $-0.35 |
| Read Transcript | Q4 | 2024 | 2024-04-25 | $-0.11 | $-0.10 |
| Read Transcript | Q3 | 2024 | 2024-01-08 | $-0.46 | $-0.28 |
| Read Transcript | Q2 | 2024 | 2023-10-04 | $-0.56 | $-0.43 |
| Read Transcript | Q1 | 2024 | 2023-06-29 | $-0.64 | $-0.52 |
| Read Transcript | Q4 | 2023 | 2023-04-27 | $-0.43 | $-0.42 |
| Read Transcript | Q3 | 2023 | 2023-01-09 | $-0.61 | $-0.56 |
| Read Transcript | Q2 | 2023 | 2022-10-06 | $-0.71 | $-0.66 |
| Read Transcript | Q1 | 2023 | 2022-06-30 | $-0.73 | $-0.40 |
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
$7.02
Stock Price
$575.59M
Market Cap
2.40K
Employees
Plymouth Meeting, PA
Location
Financial Statements
Access annual & quarterly financial statements for Accolade, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | February 28, 2021 | February 29, 2020 |
|---|---|---|---|---|---|
| Revenue | $414.29M | $363.14M | $310.02M | $170.36M | $132.51M |
| Cost of Revenue | $222.23M | $198.91M | $169.02M | $93.67M | $73.69M |
| Gross Profit | $192.06M | $164.24M | $141.00M | $76.69M | $58.82M |
| Gross Profit Ratio | 46.36% | 45.23% | 45.48% | 45.01% | 44.39% |
| Research and Development Expenses | $99.16M | $101.35M | $83.66M | $49.95M | $42.31M |
| General and Administrative Expenses | $62.12M | $81.21M | $99.11M | $31.58M | $26.15M |
| Selling and Marketing Expenses | $100.07M | $99.11M | $86.77M | $33.71M | $30.05M |
| Selling General and Administrative Expenses | $162.19M | $180.32M | $185.87M | $65.30M | $56.20M |
| Other Expenses | $45.16M | $46.38M | $42.61M | $8.21M | $8.52M |
| Operating Expenses | $306.51M | $328.05M | $312.14M | $123.46M | $107.03M |
| Cost and Expenses | $528.75M | $526.95M | $481.16M | $217.13M | $180.71M |
| Interest Income | $- | $255.00K | $2.90M | $3.72M | $2.92M |
| Interest Expense | $- | $255.00K | $2.90M | $3.72M | $2.92M |
| Depreciation and Amortization | $45.16M | $47.38M | $42.61M | $8.21M | $8.52M |
| EBITDA | $-69.29M | $-110.34M | $-130.92M | $-38.71M | $-39.80M |
| EBITDA Ratio | -16.72% | -30.39% | -42.23% | -22.72% | -30.03% |
| Operating Income | $-114.45M | $135.90M | $-171.14M | $-46.78M | $-48.20M |
| Operating Income Ratio | -27.63% | 37.42% | -55.20% | -27.46% | -36.38% |
| Total Other Income Expenses Net | $15.88M | $240.00K | $-3.04M | $-3.87M | $-3.03M |
| Income Before Tax | $-98.57M | $-463.27M | $-128.76M | $-50.65M | $-51.24M |
| Income Before Tax Ratio | -23.79% | -127.57% | -41.53% | -29.73% | -38.67% |
| Income Tax Expense | $1.24M | $-3.62M | $-5.64M | $4.00K | $129.00K |
| Net Income | $-99.81M | $-459.65M | $-123.12M | $-50.65M | $-51.37M |
| Net Income Ratio | -24.09% | -126.58% | -39.71% | -29.73% | -38.76% |
| EPS | $-1.33 | $-6.45 | $-1.93 | $-1.72 | $-1.05 |
| EPS Diluted | $-1.33 | $-6.45 | $-1.93 | $-1.72 | $-1.05 |
| Weighted Average Shares Outstanding | 74.91M | 71.28M | 63.82M | 29.37M | 48.79M |
| Weighted Average Shares Outstanding Diluted | 74.91M | 71.28M | 63.82M | 29.37M | 48.79M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | November 30, 2024 | August 31, 2024 | May 31, 2024 | February 29, 2024 | November 30, 2023 | August 31, 2023 | May 31, 2023 | February 28, 2023 | November 30, 2022 | August 31, 2022 | May 31, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 | February 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $105.06M | $106.36M | $110.47M | $124.83M | $99.37M | $96.86M | $93.23M | $99.03M | $90.95M | $87.64M | $85.53M | $93.76M | $83.45M | $73.29M | $59.53M | $59.23M | $38.44M | $36.79M | $35.89M | $44.44M |
| Cost of Revenue | $58.57M | $56.92M | $69.00M | $70.50M | $54.52M | $55.32M | $54.20M | $51.05M | $50.41M | $49.83M | $47.62M | $43.59M | $45.16M | $44.33M | $35.94M | $27.62M | $22.74M | $21.07M | $22.24M | $21.95M |
| Gross Profit | $46.49M | $49.44M | $41.46M | $54.33M | $44.85M | $41.55M | $39.02M | $47.98M | $40.53M | $37.81M | $37.91M | $50.16M | $38.29M | $28.95M | $23.59M | $31.61M | $15.70M | $15.72M | $13.65M | $22.49M |
| Gross Profit Ratio | 44.25% | 46.48% | 37.53% | 43.52% | 45.14% | 42.89% | 41.86% | 48.45% | 44.57% | 43.14% | 44.33% | 53.50% | 45.89% | 39.51% | 39.63% | 53.37% | 40.84% | 42.72% | 38.04% | 50.61% |
| Research and Development Expenses | $20.59M | $22.48M | $26.31M | $24.19M | $23.47M | $25.60M | $25.90M | $24.08M | $24.25M | $26.19M | $26.82M | $22.37M | $22.85M | $22.51M | $15.94M | $13.33M | $13.02M | $12.24M | $11.37M | $8.71M |
| General and Administrative Expenses | $16.20M | $16.54M | $16.01M | $14.31M | $15.47M | $16.26M | $16.08M | $19.91M | $20.04M | $21.02M | $20.24M | $29.47M | $21.46M | $26.17M | $22.00M | $11.05M | $8.41M | $6.45M | $5.67M | $6.03M |
| Selling and Marketing Expenses | $25.51M | $24.93M | $28.19M | $24.73M | $26.23M | $24.08M | $25.03M | $23.54M | $25.02M | $24.94M | $25.61M | $23.63M | $24.62M | $24.01M | $14.51M | $9.87M | $8.64M | $7.88M | $7.32M | $6.85M |
| Selling General and Administrative Expenses | $41.71M | $41.47M | $44.20M | $38.06M | $41.70M | $40.34M | $41.11M | $43.45M | $45.06M | $45.96M | $45.85M | $53.10M | $46.08M | $50.18M | $36.51M | $20.92M | $17.06M | $14.33M | $12.98M | $12.88M |
| Other Expenses | $106.51M | $10.64M | $94.00K | $-493.00K | $9.28M | $753.00K | $11.64M | $11.63M | $11.60M | $11.57M | $11.58M | $11.64M | $25.00K | $11.00K | $-55.00K | $13.00K | $-42.00K | $-104.00K | $-15.00K | $-9.00K |
| Operating Expenses | $168.80M | $74.58M | $70.51M | $62.25M | $41.70M | $76.75M | $78.65M | $79.16M | $80.92M | $83.72M | $84.25M | $87.11M | $80.18M | $83.71M | $61.15M | $36.37M | $32.19M | $28.62M | $26.28M | $23.69M |
| Cost and Expenses | $227.38M | $131.50M | $139.51M | $132.75M | $96.22M | $132.07M | $132.85M | $130.21M | $131.33M | $133.55M | $131.86M | $130.70M | $125.33M | $128.05M | $97.08M | $63.99M | $54.93M | $49.69M | $48.52M | $45.64M |
| Interest Income | $1.45M | $- | $- | $- | $1.71M | $1.71M | $921.00K | $- | $386.00K | $236.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $1.61M | $1.71M | $1.71M | $921.00K | $- | $386.00K | $236.00K | $634.00K | $768.00K | $743.00K | $776.00K | $618.00K | $61.00K | $35.00K | $2.35M | $1.28M | $854.00K |
| Depreciation and Amortization | $10.05M | $10.64M | $10.39M | $12.73M | $11.40M | $10.82M | $11.64M | $11.63M | $11.86M | $11.57M | $11.58M | $11.64M | $11.25M | $11.02M | $8.70M | $2.12M | $2.11M | $2.05M | $1.93M | $2.10M |
| EBITDA | $-15.81M | $-14.51M | $-18.66M | $3.41M | $-21.28M | $-24.39M | $-27.70M | $-19.56M | $-28.86M | $-34.47M | $-334.51M | $-18.29M | $-30.61M | $-63.41M | $-39.37M | $-2.62M | $-14.42M | $-10.96M | $-10.71M | $896.00K |
| EBITDA Ratio | -15.05% | -13.64% | -16.89% | 2.73% | -21.42% | -25.18% | -29.71% | -19.75% | -31.73% | -39.33% | -391.11% | -19.50% | -36.68% | -86.52% | -66.14% | -4.43% | -37.50% | -29.78% | -29.84% | 2.02% |
| Operating Income | $-122.31M | $-25.14M | $-29.05M | $-7.92M | $-31.72M | $-35.21M | $-39.63M | $-31.19M | $-40.38M | $-45.91M | $-46.33M | $-36.95M | $26.55M | $-74.44M | $-48.02M | $-4.76M | $-16.49M | $-12.90M | $-12.62M | $-1.20M |
| Operating Income Ratio | -116.42% | -23.64% | -26.30% | -6.35% | -31.92% | -36.35% | -42.51% | -31.49% | -44.40% | -52.38% | -54.17% | -39.41% | 31.81% | -101.58% | -80.66% | -8.03% | -42.89% | -35.07% | -35.17% | -2.69% |
| Total Other Income Expenses Net | $1.38M | $1.58M | $1.79M | $1.12M | $10.99M | $2.47M | $1.31M | $703.00K | $587.00K | $-366.00K | $-684.00K | $-882.00K | $-718.00K | $-765.00K | $-673.00K | $-48.00K | $-77.00K | $-2.45M | $-1.30M | $-863.00K |
| Income Before Tax | $-120.93M | $-23.56M | $-27.26M | $-6.78M | $-20.73M | $-32.74M | $-38.32M | $-30.48M | $-39.80M | $-46.27M | $-346.72M | $-30.69M | $25.83M | $-75.21M | $-48.69M | $-4.81M | $-16.57M | $-15.35M | $-13.92M | $-2.06M |
| Income Before Tax Ratio | -115.11% | -22.15% | -24.67% | -5.43% | -20.86% | -33.80% | -41.10% | -30.78% | -43.76% | -52.80% | -405.39% | -32.74% | 30.95% | -102.62% | -81.79% | -8.12% | -43.09% | -41.73% | -38.79% | -4.63% |
| Income Tax Expense | $332.00K | $374.00K | $335.00K | $729.00K | $-331.00K | $84.00K | $91.00K | $-51.00K | $77.00K | $249.00K | $-3.90M | $3.86M | $3.33M | $-12.85M | $19.00K | $-81.00K | $29.00K | $18.00K | $38.00K | $80.00K |
| Net Income | $-121.26M | $-23.93M | $-27.59M | $-7.51M | $-21.06M | $-32.83M | $-38.41M | $-30.43M | $-39.87M | $-46.52M | $-342.82M | $-34.56M | $22.50M | $-62.36M | $-48.71M | $-4.73M | $-16.59M | $-15.37M | $-13.96M | $-2.14M |
| Net Income Ratio | -115.42% | -22.50% | -24.98% | -6.01% | -21.20% | -33.89% | -41.20% | -30.73% | -43.84% | -53.08% | -400.83% | -36.86% | 26.97% | -85.09% | -81.82% | -7.98% | -43.17% | -41.78% | -38.89% | -4.81% |
| EPS | $-1.50 | $-0.30 | $-0.35 | $-0.10 | $-0.28 | $-0.43 | $-0.52 | $-0.42 | $-0.56 | $-0.66 | $-4.92 | $-0.52 | $0.34 | $-0.97 | $-0.84 | $-0.09 | $-0.32 | $-0.47 | $-0.30 | $-0.05 |
| EPS Diluted | $-1.50 | $-0.30 | $-0.35 | $-0.10 | $-0.28 | $-0.43 | $-0.52 | $-0.42 | $-0.56 | $-0.66 | $-4.92 | $-0.51 | $0.31 | $-0.97 | $-0.84 | $-0.08 | $-0.32 | $-0.47 | $-0.30 | $-0.05 |
| Weighted Average Shares Outstanding | 80.65M | 80.07M | 78.12M | 77.35M | 76.14M | 75.49M | 73.18M | 72.08M | 71.23M | 70.48M | 69.74M | 66.84M | 65.42M | 64.29M | 58.26M | 55.39M | 51.58M | 33.03M | 46.65M | 46.65M |
| Weighted Average Shares Outstanding Diluted | 80.65M | 80.07M | 78.12M | 77.35M | 76.14M | 75.49M | 73.18M | 72.08M | 71.23M | 70.48M | 69.74M | 67.30M | 71.49M | 64.40M | 58.26M | 58.26M | 51.58M | 33.03M | 46.65M | 46.65M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | February 28, 2021 | February 29, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $185.72M | $321.08M | $365.85M | $433.88M | $84.32M |
| Short Term Investments | $51.31M | $- | $- | $- | $- |
| Cash and Short Term Investments | $237.03M | $321.08M | $365.85M | $433.88M | $84.32M |
| Net Receivables | $27.70M | $26.70M | $30.80M | $11.84M | $1.19M |
| Inventory | $-15.81M | $4.02M | $3.02M | $2.30M | $1.65M |
| Other Current Assets | $35.98M | $18.17M | $12.48M | $8.26M | $14.59M |
| Total Current Assets | $284.91M | $365.95M | $409.14M | $453.98M | $100.10M |
| Property Plant Equipment Net | $47.48M | $44.29M | $44.92M | $9.23M | $13.62M |
| Goodwill | $278.19M | $278.19M | $577.90M | $4.01M | $4.01M |
| Intangible Assets | $165.41M | $203.20M | $244.69M | $604.00K | $2.05M |
| Goodwill and Intangible Assets | $443.60M | $481.39M | $822.59M | $4.62M | $6.07M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $12.16M | $11.44M | $8.88M | $7.68M | $4.62M |
| Total Non-Current Assets | $503.24M | $537.12M | $876.39M | $21.53M | $24.31M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $788.15M | $903.07M | $1.29B | $475.51M | $124.41M |
| Account Payables | $13.75M | $10.15M | $7.84M | $7.39M | $5.27M |
| Short Term Debt | $7.09M | $7.88M | $7.18M | $- | $- |
| Tax Payables | $1.73M | $528.00K | $769.00K | $1.07M | $512.00K |
| Deferred Revenue | $34.77M | $50.88M | $47.14M | $30.89M | $33.59M |
| Other Current Liabilities | $50.51M | $65.66M | $65.09M | $44.73M | $64.17M |
| Total Current Liabilities | $107.85M | $119.41M | $111.75M | $79.08M | $69.96M |
| Long Term Debt | $234.56M | $309.51M | $313.15M | $- | $21.14M |
| Deferred Revenue Non-Current | $121.00K | $154.00K | $268.00K | $395.00K | $396.00K |
| Deferred Tax Liabilities Non-Current | $1 | $- | $- | $- | $- |
| Other Non-Current Liabilities | $156.00K | $203.00K | $4.56M | $5.19M | $56.69M |
| Total Non-Current Liabilities | $234.84M | $309.87M | $317.98M | $5.59M | $78.23M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $342.69M | $429.28M | $429.74M | $84.66M | $148.19M |
| Preferred Stock | $- | $0 | $- | $475.51M | $233.02M |
| Common Stock | $8.00K | $7.00K | $7.00K | $6.00K | $4.00K |
| Retained Earnings | $-1.05B | $-954.29M | $-494.64M | $-371.52M | $-320.87M |
| Accumulated Other Comprehensive Income Loss | $-47.00K | $-0 | $- | $-475.51M | $-233.02M |
| Other Total Stockholders Equity | $1.50B | $1.43B | $1.35B | $286.85M | $530.12M |
| Total Stockholders Equity | $445.46M | $473.79M | $855.79M | $390.85M | $-23.77M |
| Total Equity | $445.46M | $473.79M | $855.79M | $390.85M | $-23.77M |
| Total Liabilities and Stockholders Equity | $788.15M | $903.07M | $1.29B | $475.51M | $124.41M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $788.15M | $903.07M | $1.29B | $475.51M | $124.41M |
| Total Investments | $51.31M | $- | $- | $- | $- |
| Total Debt | $241.65M | $316.80M | $319.74M | $- | $72.31M |
| Net Debt | $55.93M | $-4.29M | $-46.11M | $-433.88M | $-12.01M |
Balance Sheet Charts
| Breakdown | November 30, 2024 | August 31, 2024 | May 31, 2024 | February 29, 2024 | November 30, 2023 | August 31, 2023 | May 31, 2023 | February 28, 2023 | November 30, 2022 | August 31, 2022 | May 31, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 | February 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $185.92M | $173.31M | $188.71M | $185.72M | $230.02M | $292.19M | $302.87M | $321.08M | $325.64M | $330.63M | $335.63M | $365.85M | $365.98M | $384.00M | $325.51M | $433.88M | $418.94M | $222.11M | $77.68M | $84.32M |
| Short Term Investments | $39.56M | $61.03M | $41.93M | $51.31M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $100.00M | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $225.48M | $234.35M | $230.64M | $237.03M | $230.02M | $292.19M | $302.87M | $321.08M | $325.64M | $330.63M | $335.63M | $365.85M | $365.98M | $384.00M | $425.51M | $433.88M | $418.94M | $222.11M | $77.68M | $84.32M |
| Net Receivables | $30.69M | $25.22M | $27.71M | $27.70M | $25.56M | $25.31M | $26.30M | $26.70M | $24.18M | $30.61M | $28.48M | $30.80M | $25.90M | $18.72M | $18.02M | $11.84M | $16.77M | $10.77M | $3.21M | $1.19M |
| Inventory | $- | $- | $- | $1 | $4.46M | $4.47M | $3.93M | $- | $-3.70M | $1 | $3.18M | $3.02M | $2.96M | $2.86M | $2.49M | $2.30M | $2.21M | $1.94M | $1.67M | $1.65M |
| Other Current Assets | $16.27M | $15.17M | $16.91M | $31.62M | $16.52M | $28.57M | $19.30M | $18.17M | $16.41M | $13.55M | $13.46M | $12.48M | $15.67M | $14.89M | $9.93M | $8.26M | $8.81M | $9.96M | $15.87M | $14.59M |
| Total Current Assets | $272.45M | $274.74M | $271.01M | $280.54M | $272.09M | $336.26M | $348.47M | $365.95M | $366.23M | $374.79M | $377.57M | $409.14M | $407.56M | $417.61M | $453.46M | $453.98M | $444.51M | $242.84M | $96.75M | $100.10M |
| Property Plant Equipment Net | $43.24M | $44.57M | $46.77M | $47.48M | $48.07M | $44.44M | $44.69M | $44.29M | $44.50M | $44.61M | $45.66M | $44.92M | $11.96M | $12.18M | $12.16M | $9.23M | $10.50M | $11.73M | $12.60M | $13.62M |
| Goodwill | $181.73M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $278.19M | $577.90M | $579.58M | $575.66M | $214.18M | $4.01M | $4.01M | $4.01M | $4.01M | $4.01M |
| Intangible Assets | $139.31M | $147.64M | $156.52M | $165.41M | $174.55M | $183.69M | $192.83M | $203.20M | $213.57M | $223.95M | $234.32M | $244.69M | $255.13M | $255.17M | $203.50M | $604.00K | $967.00K | $1.33M | $1.69M | $2.05M |
| Goodwill and Intangible Assets | $321.05M | $425.83M | $434.71M | $443.60M | $452.74M | $461.88M | $471.02M | $481.39M | $491.76M | $502.14M | $512.51M | $822.59M | $834.71M | $830.83M | $417.68M | $4.62M | $4.98M | $5.34M | $5.71M | $6.07M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $10.72M | $10.93M | $14.88M | $16.53M | $12.57M | $11.74M | $11.53M | $11.44M | $11.30M | $10.15M | $8.72M | $8.88M | $9.12M | $9.18M | $8.20M | $7.68M | $7.51M | $6.97M | $5.42M | $4.62M |
| Total Non-Current Assets | $375.00M | $481.34M | $496.36M | $507.61M | $513.38M | $518.06M | $527.23M | $537.12M | $547.56M | $556.90M | $566.89M | $876.39M | $855.80M | $852.18M | $438.04M | $21.53M | $22.98M | $24.04M | $23.73M | $24.31M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $647.45M | $756.07M | $767.37M | $788.15M | $785.47M | $854.32M | $875.71M | $903.07M | $913.79M | $931.68M | $944.45M | $1.29B | $1.26B | $1.27B | $891.49M | $475.51M | $467.50M | $266.88M | $120.48M | $124.41M |
| Account Payables | $10.34M | $9.03M | $8.14M | $13.75M | $12.67M | $7.10M | $5.46M | $10.15M | $9.99M | $11.09M | $7.78M | $7.84M | $5.74M | $8.70M | $7.09M | $7.39M | $4.14M | $3.81M | $4.94M | $5.27M |
| Short Term Debt | $14.68M | $14.14M | $14.38M | $7.09M | $13.80M | $6.36M | $6.92M | $7.88M | $14.78M | $14.35M | $7.02M | $7.18M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $1.73M | $- | $- | $- | $528.00K | $- | $- | $- | $769.00K | $- | $- | $- | $1.07M | $- | $- | $- | $512.00K |
| Deferred Revenue | $38.26M | $40.71M | $38.74M | $34.77M | $52.77M | $57.65M | $58.95M | $35.19M | $52.74M | $53.52M | $47.99M | $47.14M | $49.44M | $49.80M | $39.40M | $30.89M | $37.88M | $37.51M | $38.72M | $33.59M |
| Other Current Liabilities | $40.29M | $37.15M | $37.17M | $50.51M | $36.43M | $95.55M | $100.36M | $65.66M | $48.34M | $42.22M | $80.69M | $95.96M | $135.72M | $197.58M | $160.40M | $70.61M | $34.88M | $32.35M | $70.45M | $35.25M |
| Total Current Liabilities | $103.58M | $101.02M | $98.44M | $107.85M | $115.67M | $109.00M | $112.74M | $119.41M | $116.62M | $112.66M | $95.48M | $111.75M | $184.60M | $249.40M | $167.49M | $79.08M | $73.44M | $68.94M | $75.39M | $69.96M |
| Long Term Debt | $21.15M | $231.74M | $233.40M | $234.56M | $234.80M | $307.41M | $308.48M | $309.51M | $310.76M | $312.22M | $313.62M | $313.15M | $280.26M | $279.85M | $279.43M | $- | $- | $- | $72.52M | $21.14M |
| Deferred Revenue Non-Current | $66.00K | $85.00K | $102.00K | $121.00K | $120.00K | $97.00K | $142.00K | $154.00K | $256.00K | $284.00K | $280.00K | $268.00K | $299.00K | $353.00K | $448.00K | $395.00K | $394.00K | $322.00K | $426.00K | $396.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $24.61M | $26.08M | $- | $- | $- | $- | $- | $- | $- | $- | $-225.38M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $209.66M | $153.00K | $157.00K | $156.00K | $165.00K | $165.00K | $168.00K | $203.00K | $203.00K | $203.00K | $563.00K | $4.56M | $9.49M | $6.64M | $7.01M | $5.19M | $5.38M | $5.52M | $238.64M | $56.69M |
| Total Non-Current Liabilities | $230.87M | $231.98M | $233.66M | $234.84M | $235.08M | $307.67M | $308.79M | $309.87M | $311.22M | $312.71M | $314.47M | $317.98M | $290.05M | $286.84M | $286.90M | $5.59M | $5.77M | $5.84M | $311.59M | $78.23M |
| Other Liabilities | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $334.45M | $333.00M | $332.10M | $342.69M | $350.75M | $416.68M | $421.53M | $429.28M | $427.84M | $425.37M | $409.95M | $429.74M | $474.65M | $536.24M | $454.38M | $84.66M | $79.21M | $74.77M | $386.98M | $148.19M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $1 | $- | $0 | $- | $467.50M | $266.88M | $233.02M | $233.02M |
| Common Stock | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $5.00K | $5.00K | $2.00K | $4.00K |
| Retained Earnings | $-1.23B | $-1.11B | $-1.08B | $-1.05B | $-1.05B | $-1.03B | $-992.70M | $-954.29M | $-923.86M | $-883.99M | $-837.47M | $-494.64M | $-460.09M | $-482.59M | $-420.23M | $-371.52M | $-366.79M | $-350.20M | $-334.83M | $-320.87M |
| Accumulated Other Comprehensive Income Loss | $24.00K | $26.00K | $-34.00K | $-47.00K | $- | $- | $- | $- | $-0 | $- | $0 | $- | $0 | $- | $-0 | $0 | $-467.50M | $-266.88M | $-0 | $-50.61M |
| Other Total Stockholders Equity | $1.54B | $1.53B | $1.52B | $1.50B | $1.48B | $1.46B | $1.45B | $1.43B | $1.41B | $1.39B | $1.37B | $1.35B | $1.25B | $1.22B | $857.33M | $762.36M | $287.58M | $275.42M | $-164.69M | $165.29M |
| Total Stockholders Equity | $313.00M | $423.07M | $435.26M | $445.46M | $434.72M | $437.64M | $454.18M | $473.79M | $485.95M | $506.31M | $534.51M | $855.79M | $788.70M | $733.56M | $437.11M | $390.85M | $388.29M | $192.10M | $-266.50M | $-23.77M |
| Total Equity | $313.00M | $423.07M | $435.26M | $445.46M | $434.72M | $437.64M | $454.18M | $473.79M | $485.95M | $506.31M | $534.51M | $855.79M | $788.70M | $733.56M | $437.11M | $390.85M | $388.29M | $192.10M | $-266.50M | $-23.77M |
| Total Liabilities and Stockholders Equity | $647.45M | $756.07M | $767.37M | $788.15M | $785.47M | $854.32M | $875.71M | $903.07M | $913.79M | $931.68M | $944.45M | $1.29B | $1.26B | $1.27B | $891.49M | $475.51M | $467.50M | $266.88M | $120.48M | $124.41M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $647.45M | $756.07M | $767.37M | $788.15M | $785.47M | $854.32M | $875.71M | $903.07M | $913.79M | $931.68M | $944.45M | $1.29B | $1.26B | $1.27B | $891.49M | $475.51M | $467.50M | $266.88M | $120.48M | $124.41M |
| Total Investments | $39.56M | $61.03M | $41.93M | $51.31M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $100.00M | $- | $- | $- | $- | $- |
| Total Debt | $28.49M | $238.81M | $240.59M | $241.65M | $241.70M | $313.77M | $315.40M | $317.39M | $318.15M | $319.39M | $320.64M | $319.74M | $280.26M | $279.85M | $279.43M | $- | $- | $- | $72.52M | $72.31M |
| Net Debt | $-157.43M | $65.49M | $51.89M | $55.93M | $11.68M | $21.58M | $12.53M | $-3.69M | $-7.48M | $-11.24M | $-14.99M | $-46.11M | $-85.72M | $-104.15M | $-46.07M | $-433.88M | $-418.94M | $-222.11M | $-5.16M | $-12.01M |
Annual Cash Flow
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | February 28, 2021 | February 29, 2020 |
|---|---|---|---|---|---|
| Net Income | $-99.81M | $-459.65M | $-123.12M | $-50.65M | $-51.37M |
| Depreciation and Amortization | $45.16M | $46.38M | $42.61M | $8.21M | $8.52M |
| Deferred Income Tax | $- | $-4.00M | $-6.13M | $- | $6.18M |
| Stock Based Compensation | $60.94M | $72.64M | $72.94M | $9.58M | $11.89M |
| Change in Working Capital | $-19.96M | $-1.14M | $-7.84M | $3.72M | $-5.40M |
| Accounts Receivables | $-1.01M | $4.11M | $-11.83M | $-10.65M | $-683.00K |
| Inventory | $- | $- | $- | $7.66M | $-5.16M |
| Accounts Payables | $3.38M | $1.13M | $69.00K | $2.99M | $5.84M |
| Other Working Capital | $-22.34M | $-6.38M | $3.92M | $3.72M | $-5.40M |
| Other Non Cash Items | $-2.51M | $305.06M | $-40.80M | $3.91M | $1.82M |
| Net Cash Provided by Operating Activities | $-16.17M | $-40.70M | $-62.35M | $-25.23M | $-34.25M |
| Investments in Property Plant and Equipment | $-4.93M | $-7.23M | $-3.62M | $-2.37M | $-3.31M |
| Acquisitions Net | $- | $- | $-260.00M | $-58.00K | $-206.00K |
| Purchases of Investments | $-51.15M | $- | $-100.00M | $- | $- |
| Sales Maturities of Investments | $- | $- | $100.00M | $- | $- |
| Other Investing Activities | $-7.55M | $-5.12M | $-1.10M | $-58.00K | $- |
| Net Cash Used for Investing Activities | $-63.63M | $-7.23M | $-263.61M | $-2.42M | $-3.52M |
| Debt Repayment | $-65.81M | $- | $287.50M | $-22.75M | $1.66M |
| Common Stock Issued | $- | $4.99M | $455.59M | $439.41M | $26.56M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-355.00K | $3.16M | $-29.57M | $451.14M | $26.56M |
| Net Cash Used Provided by Financing Activities | $-55.57M | $3.16M | $257.93M | $428.38M | $28.22M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-135.37M | $-44.77M | $-68.03M | $400.73M | $-9.55M |
| Cash at End of Period | $185.72M | $321.08M | $365.85M | $433.88M | $33.16M |
| Cash at Beginning of Period | $321.08M | $365.85M | $433.88M | $33.16M | $42.70M |
| Operating Cash Flow | $-16.17M | $-40.70M | $-62.35M | $-25.23M | $-34.25M |
| Capital Expenditure | $-12.48M | $-7.23M | $-3.62M | $-2.37M | $-3.31M |
| Free Cash Flow | $-28.65M | $-47.93M | $-65.97M | $-27.60M | $-37.56M |
Cash Flow Charts
| Breakdown | November 30, 2024 | August 31, 2024 | May 31, 2024 | February 29, 2024 | November 30, 2023 | August 31, 2023 | May 31, 2023 | February 28, 2023 | November 30, 2022 | August 31, 2022 | May 31, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 | February 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-121.26M | $-23.93M | $-27.59M | $-7.51M | $-21.06M | $-32.83M | $-38.41M | $-30.43M | $-39.87M | $-46.52M | $-342.82M | $-34.56M | $22.50M | $-62.36M | $-48.71M | $-4.73M | $-16.59M | $-15.37M | $-13.96M | $-2.14M |
| Depreciation and Amortization | $10.05M | $10.64M | $10.39M | $12.73M | $11.40M | $10.82M | $11.64M | $11.63M | $11.60M | $11.57M | $11.58M | $11.64M | $11.25M | $11.02M | $8.70M | $2.12M | $2.11M | $2.05M | $1.93M | $2.10M |
| Deferred Income Tax | $- | $- | $- | $7.97M | $-9.27M | $- | $1.29M | $-138.00K | $-4.00M | $140.00K | $-4.00M | $3.53M | $3.21M | $-12.87M | $- | $- | $- | $- | $- | $6.18M |
| Stock Based Compensation | $10.05M | $11.68M | $15.31M | $15.29M | $15.64M | $15.73M | $14.28M | $17.84M | $17.91M | $17.51M | $19.39M | $27.11M | $18.38M | $19.77M | $7.67M | $3.27M | $2.95M | $2.10M | $1.26M | $1.11M |
| Change in Working Capital | $1.61M | $4.74M | $-6.35M | $-14.65M | $6.45M | $-3.41M | $-8.35M | $-2.97M | $4.38M | $12.99M | $-15.55M | $-4.31M | $-9.44M | $12.63M | $-6.72M | $8.41M | $-1.26M | $-5.34M | $1.92M | $-18.80M |
| Accounts Receivables | $-5.47M | $2.49M | $-9.00K | $-2.15M | $-243.00K | $985.00K | $396.00K | $-2.51M | $6.62M | $-2.13M | $2.32M | $-11.83M | $-7.18M | $1.85M | $-409.00K | $-10.65M | $-6.00M | $-7.57M | $-2.02M | $-806.00K |
| Inventory | $- | $- | $- | $4.80M | $-1.19M | $-1.11M | $-2.50M | $- | $- | $-2.75M | $- | $13.73M | $- | $- | $-385.00K | $16.75M | $- | $- | $-1.83M | $- |
| Accounts Payables | $-66.00K | $1.28M | $-5.35M | $3.51M | $1.43M | $125.00K | $-1.69M | $887.00K | $244.00K | $4.88M | $-1.26M | $-1.90M | $-1.61M | $-535.00K | $268.00K | $2.99M | $- | $- | $-1.68M | $- |
| Other Working Capital | $7.16M | $969.00K | $-991.00K | $-16.02M | $6.45M | $-3.41M | $-4.56M | $-1.34M | $-2.48M | $12.99M | $-16.61M | $-4.31M | $-9.44M | $12.63M | $-6.19M | $-681.00K | $-1.26M | $-5.34M | $7.45M | $-18.80M |
| Other Non Cash Items | $89.81M | $1.03M | $42.58M | $39.47M | $2.04M | $1.65M | $262.00K | $1.51M | $5.29M | $1.31M | $300.94M | $-5.69M | $-67.32M | $20.77M | $11.44M | $1.33M | $526.00K | $1.52M | $534.00K | $1.29M |
| Net Cash Provided by Operating Activities | $-9.73M | $4.14M | $-7.12M | $5.95M | $5.21M | $-8.04M | $-19.29M | $-2.56M | $-4.69M | $-2.99M | $-30.46M | $-2.28M | $-21.42M | $-11.03M | $-27.61M | $10.40M | $-12.27M | $-15.04M | $-8.32M | $-10.26M |
| Investments in Property Plant and Equipment | $1.28M | $-358.00K | $-1.96M | $-2.11M | $-3.71M | $-3.29M | $-3.38M | $-204.00K | $-1.91M | $-1.63M | $-1.27M | $-701.00K | $-987.00K | $-1.23M | $-701.00K | $-491.00K | $-519.00K | $-817.00K | $-538.00K | $-846.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $169.00K | $1.71M | $-33.86M | $-228.01M | $- | $- | $-58.00K | $- | $- |
| Purchases of Investments | $-4.92M | $-36.00M | $- | $-51.15M | $- | $- | $- | $- | $- | $- | $- | $740.00K | $- | $- | $-100.00M | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $27.00M | $17.50M | $10.00M | $- | $- | $- | $- | $- | $- | $- | $- | $100.00M | $- | $100.00M | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-2.15M | $-691.00K | $8.76M | $-52.22M | $-1.78M | $-2.20M | $-2.50M | $-2.21M | $-1.42M | $-733.00K | $-766.00K | $-100.74M | $-263.00K | $100.00M | $-100.00M | $- | $- | $-58.00K | $-289.00K | $- |
| Net Cash Used for Investing Activities | $21.20M | $-19.55M | $8.04M | $-53.25M | $-3.71M | $-3.29M | $-3.38M | $-2.41M | $-1.91M | $-1.63M | $-1.27M | $-532.00K | $721.00K | $64.91M | $-328.71M | $-491.00K | $-519.00K | $-875.00K | $-538.00K | $-846.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $287.50M | $- | $- | $- | $51.17M | $- |
| Common Stock Issued | $-2.08M | $11.00K | $2.07M | $3.00M | $- | $641.00K | $4.45M | $- | $1.61M | $1.46M | $1.51M | $455.59M | $2.68M | $4.88M | $116.19M | $-68.00K | $207.80M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.14M | $11.00K | $2.07M | $3.00M | $-66.16M | $641.00K | $4.45M | $418.00K | $1.61M | $-370.00K | $1.51M | $2.69M | $2.68M | $4.62M | $-39.55M | $5.04M | $1.82M | $160.34M | $2.22M | $4.61M |
| Net Cash Used Provided by Financing Activities | $1.14M | $11.00K | $2.07M | $3.00M | $-63.66M | $641.00K | $4.45M | $418.00K | $1.61M | $-370.00K | $1.51M | $2.69M | $2.68M | $4.62M | $247.95M | $5.04M | $209.62M | $160.34M | $53.38M | $4.61M |
| Effect of Forex Changes on Cash | $- | $- | $- | $-106.59M | $78.98M | $27.61M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $12.61M | $-15.39M | $2.99M | $-44.30M | $-62.17M | $-10.68M | $-18.21M | $-4.55M | $-5.00M | $-5.00M | $-30.23M | $-129.00K | $-18.02M | $58.49M | $-108.38M | $14.95M | $196.83M | $144.43M | $44.53M | $-6.50M |
| Cash at End of Period | $185.92M | $173.31M | $188.71M | $185.72M | $230.02M | $292.19M | $302.87M | $321.08M | $325.64M | $330.63M | $335.63M | $365.85M | $365.98M | $384.00M | $325.51M | $433.88M | $418.94M | $222.11M | $77.68M | $33.16M |
| Cash at Beginning of Period | $173.31M | $188.71M | $185.72M | $230.02M | $292.19M | $302.87M | $321.08M | $325.64M | $330.63M | $335.63M | $365.85M | $365.98M | $384.00M | $325.51M | $433.88M | $418.94M | $222.11M | $77.68M | $33.16M | $39.65M |
| Operating Cash Flow | $-9.73M | $4.14M | $-7.12M | $5.95M | $5.21M | $-8.04M | $-19.29M | $-2.56M | $-4.69M | $-2.99M | $-30.46M | $-2.28M | $-21.42M | $-11.03M | $-27.61M | $10.40M | $-12.27M | $-15.04M | $-8.32M | $-10.26M |
| Capital Expenditure | $1.97M | $-1.05M | $-1.96M | $-2.11M | $-3.71M | $-3.29M | $-3.38M | $-2.41M | $-1.91M | $-1.63M | $-1.27M | $-701.00K | $-987.00K | $-1.23M | $-701.00K | $-491.00K | $-519.00K | $-817.00K | $-538.00K | $-846.00K |
| Free Cash Flow | $-7.77M | $3.10M | $-9.07M | $3.84M | $1.49M | $-11.32M | $-22.66M | $-4.97M | $-6.60M | $-4.62M | $-31.73M | $-2.98M | $-22.41M | $-12.26M | $-28.32M | $9.90M | $-12.79M | $-15.86M | $-8.86M | $-11.11M |
Accolade Dividends
Explore Accolade's dividend history, including dividend yield, payout ratio, and historical payments.
Accolade News
Read the latest news about Accolade, including recent articles, headlines, and updates.
Transcarent Completes Merger With Accolade
SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. With the completion of the transaction, Transcarent will offer a health and care experience that is unmatched in its abil.
Accolade Stockholders Approve Merger Between Accolade and Transcarent
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission.
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem
Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE , March 6, 2025 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) has partnered with Oshi Health , a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Accolade and its board.
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies.
Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Accolade (NASDAQ: ACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Accolade stockholders will receive $7.03 per share in cash, which represents a total equity value of ap.
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Accolade: A GARP Stock Trading Well Under 1X Revenues
Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overreaction to a minor revenue guidance decline. Its stock trades at a significant discount to its peers despite growing faster than all but one.
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days.
Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating
TORONTO--(BUSINESS WIRE)--Porter Airlines has been rated a 2025 Four Star Major Airline by passengers, certified by the Airline Passenger Experience Association (APEX). The APEX Five Star and Four Star Airlines Awards are the only global awards based entirely on neutral, third-party passenger feedback. They are a result of passenger ratings of almost one million flights across nearly 600 airlines around the world, certified by APEX in partnership with TripIt® from Concur®. “Receiving this ratin.
Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Accolade Welcomes Renalogic to Trusted Partner Ecosystem
Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). SEATTLE , Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions.
Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript
Accolade, Inc. (NASDAQ:ACCD ) Q2 2025 Earnings Conference Call October 8, 2024 8:00 AM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Jeff Garro - Stephens Inc. Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jared Haase - William Blair Stephanie Davis - Barclays Allen Lutz - Bank of America Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Operator Ladies and gentlemen, thank you for standing by. Welcome to Accolade Second Quarter 2025 Earnings Results Conference Call.
Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30
On October 8, 2024, Accolade Inc (ACCD, Financial) released its 8-K filing detailing the financial results for the fiscal second quarter ending August 31, 2024. Accolade Inc, a company offering technology-enabled solutions to navigate the healthcare system, reported a revenue of $106.4 million, exceeding the analyst estimate of $105.01 million.
Accolade to Announce Fiscal Second Quarter 2025 Financial Results
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ACCD.